Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Adjoint-based OPTimization of deflection-based cerebral embolic protection devices for reducing stroke risk in Transcatheter Aortic Valve Implantation (OPTAVI)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Mathematics
Countries involved: United Kingdom
Call: Individual Fellowships (H2020-MSCA-IF-2019, 2019)
Start date: 2021-10-01
End date: 2023-09-30
Duration (months): 24.0
Total project cost (EUR): 212933.76
EU funding (EUR): 212933.76
Participants: 1
Project status: SIGNED

Transcatheter aortic valve implantation (TAVI) has quickly become the clinical standard for patients with medium to high risk for surgery. Despite being a promising treatment for aortic valve disease in the elderly, stroke remains a major complication of TAVI. Large randomized clinical trials reported stroke within 30 days in 5-7% of the patients undergoing TAVI . TCD ultrasound imaging has showed cerebral embolic signals in 100% of the TAVI patients, mainly during valve deployment. Cerebral embolic protection devices (CEPD) have been developed to reduce the migration of debris to the brain during TAVI, and resulted in 44-46% decrease in brain lesions. Despite this progress, the risk still remains significant. Current CEPDs are based on fairly simple-minded ideas, e.g. placing filters inside brachiocephalic and left common cartoid arteries (e.g. Sentinel), or simply covering the arteries in the aortic arch with a filter to deflect the debris downstream (e.g. TriGaurd HDH). Because the flow here is turbulent and laden with solid particles, more advanced physical understanding is needed to examine and/or enhance the hydrodynamic efficacy of CEPDs. This project aims at creating a 3D nonlinear adjoint-based framework on top of an existing GPU-accelerated flow solver for optimization of the CEPDs performance when exposed to the particle-laden turbulent flow in the aorta. First, the flow through a model of a prosthetic heart valve will be extended to include the full geometry of the thoracic aorta using an Immersed Boundary Method. Second, a Lagrangian model for finite-sized particles representing embolic debris will be coupled into the flow solver. Third, a deflection-based CEPD geometry will be introduced into the model. Fourth, nonlinear adjoint-based variational capabilities will be added on top of the particle-laden turbulent flow solver. Iterative direct-adjoint looping simulations will be then performed to obtain a CEPD design with maximum cerebral protection.

Keywords: adjoint based optimisation,unsteady and turbulent flow control,high fidelity cfd,tavi,cerebral embolic protection device,gpu based supercomputing,immersed boundary method,particle laden flows
Exploitation of a low-field scanner for physiotherapy and rheumatology (PR scanner)

Framework: Horizon 2020 — Excellent Science
Programme: Future and Emerging Technologies (FET)
Theme: EIC Pathfinder
Destination: Novel ideas for radically new technologies
Action type: Coordination and support actions
Countries involved: Spain,Netherlands
Call: FET Innovation Launchpad (H2020-FETOPEN-2018-2019-2020-4, 2020)
Start date: 2021-04-01
End date: 2022-09-30
Duration (months): 18.0
Total project cost (EUR): 134285.71
EU funding (EUR): 100000.0
Participants: 2
Project status: CLOSED

Histo-MRI is a FET-Open project finishing at the end of 2020, coordinated by CSIC and with the key participation of LUMC. The main goal of Histo-MRI was the development of a new imaging technology capable of unprecedented spatial and temporal resolution. As part of this highly ambitious challenge, we have developed disruptive hardware, as well as cutting-edge spatial encoding and image reconstruction methods. One particularly successful line of research within Histo-MRI was low field MRI, where we have built a single-purpose, affordable Physiotherapy/Rheumatology scanner (the PR Gen I scanner), patented four families of MRI methods, and created a new open-source high-performance MR console (MaRCoS: Magnetic Resonance Control System). PhysioMRI Tech S.L. is a recent spin-off from the Histo-MRI project, participated by both CSIC and LUMC members. Ultimately, we aim to commercialize high performance, low field setups massively in sports clubs and physiotherapy and rheumatology clinics. We will consider this project successful if by its end we have deployed the commercial plan we have devised for our PR Gen I scanner, updated with MaRCoS and advanced encoding and reconstruction methods. We envision three stages in this process: i) in the first six months, we will duplicate the original LUMC PR – Gen I system at the PhysMRI laboratories and benchmark its performance; ii) next, we will go to a second round of investment; and iii) we will build ten systems and site them at sports clubs, physiotherapy and rheumatology clinics, where we will run these systems in real clinical environments. Once these steps are accomplished, we will start the medical certification processes in Europe and USA, right after the end of this project.

Keywords: physiotherapy and rheumatology,extremity mri,low cost mri,low field mri
INDustrial EXploitation of the genesYS cross-domain architecture (INDEXYS)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Embedded Computing Systems
Action type: Collaborative project
Partnership: ARTEMIS (Art-185)
Countries involved: Austria,Germany,Netherlands,Germany,Netherlands,Germany,Germany,Hungary
Call:  (ARTEMIS-2008-1, 2008)
Start date: 2009-04-01
End date: 2012-03-31
Duration (months): 36.0
Total project cost (EUR): 7344281.06
EU funding (EUR): 1226494.94
Participants: 10
Project status: CLOSED

The objective of INDEXYS (INDustrial EXploitation of the genesYS cross-domain architecture) is to tangibly realize industrial implementations of cross-domain architectural concepts developed in the GENESYS project in three domains: automotive, aerospace and railway, thereby relating to ARTEMIS-JU Industrial Priority: “Reference designs and architectures”. GENESYS (Generic Embedded System Platform) is developing a cross-domain architecture according to requirements of the ARTEMIS Strategic Research Agenda. The GENESYS architectural style supports a composable, robust, and comprehensible component-based framework with strict separation of computation from message-based communication. So components can be massively reused in differing contexts. In the GENESYS architecture three integration levels of components are distinguished: chip-level, where IP cores communicate via a deterministic Network-on-a-Chip (NoC), device level, where chips communicate within a device, and system level, where devices communicate in an open or closed environment. INDEXYS expands the GENESYS approach by implementing and integrating architectural services into prevailing (real-world!) platform solutions. A key goal of INDEXYS is legacy integration, for platform providers - by integrating new architectural services into legacy platforms - and for platform users - by supporting legacy applications. INDEXYS addresses robustness wrt. design faults and physical faults by diversity and component replication. INDEXYS targets ARTEMIS-JU Sub-Programme 5: “Computing environments for embedded systems” by developing new concepts for composable component integration, re-usable dependability services, and a cross-domain tool chain based on OMGs Model Driven Architecture. By fostering development of re-usable dependable products and associated services, INDEXYS significantly contributes to competitive advantages of European players in the transportation industries.

Keywords: embedded,architecture,composability,cross-domain
EMbedded MONitoring (EMMON)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Embedded Computing Systems
Action type: Collaborative project
Partnership: ARTEMIS (Art-185)
Countries involved: Portugal,Spain,Ireland,Greece,Italy,United Kingdom,United Kingdom
Call:  (ARTEMIS-2008-1, 2008)
Start date: 2009-03-01
End date: 2012-05-31
Duration (months): 39.0
Total project cost (EUR): 2576275.0
EU funding (EUR): 430237.92
Participants: 9
Project status: CLOSED

The vision of smart locations is of significant societal interest today. For example, a smart city can monitor its levels and distribution of air pollution and give recommendation to European citizen about where to walk and where to drive. This helps to improve sustainability of urban life. This societal vision requires however that monitoring of huge geographical extensions is performed in real time. The EMMON project aims to allow such monitoring using Wireless Sensor Network (WSN) devices – small communicating & cooperative nodes with sensors. In order to achieve this ambition, EMMON will perform technological research at the level of devices, in new, efficient, and low power consumption communication protocols, embedded software with better overall energy efficiency, secure, fault-tolerant and reliable middleware for large scale monitoring and remote command & control operational systems for end-users. The project will deliver results in all these fields. All research and development efforts are targeted to allow the use of thousands of devices in distributed large scale networks. The objective is to accomplish that these embedded devices can be placed in the environment to perform continuous monitoring and situation analysis, targeted at specific scenarios (water pipelines, urban quality of life, forest and marine environments, civil protection) detecting abnormal variations and broadcast rapidly alarms and alerts. The quantified goal of the project is to create technologies that allow effective monitoring with 10,000 to 100,000 devices, monitoring an area of 50 square km in a real world scenarios. This would advance WSN deployment size by one order of magnitude. The consortium will use simulation to test if advancements of two orders of magnitude are possible with the EMMON resulting technology.

Keywords: wireless sensor networks,large scale,dependability,wsn
BeTheCuRE (BTCURE)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: Belgium,Sweden,Netherlands,Switzerland,United Kingdom,Germany,Netherlands,Austria,Norway,Germany,United Kingdom,United Kingdom,Netherlands,Spain,France,Ireland,Czechia,Greece,France,United States,Germany,Denmark,Germany,France,United Kingdom,Sweden,Sweden,France,Italy
Call:  (IMI-JU-02-2009, 2009)
Start date: 2011-04-01
End date: 2017-03-31
Duration (months): 72.0
Total project cost (EUR): 39371092.0
EU funding (EUR): 17362872.0
Participants: 39
Project status: CLOSED

BTCure is based on the recognition that RA is a heterogeneous disease where a major subset involves adaptive immunity, and that animal models have to develop the line with the different subsets of the human diseases in order to be optimally used for drug discovery and drug evaluation. Our aim is to develop an understanding of the early process in human arthritis subsets and the animal models that will enable us and EFPIA partners to develop precise and eventually curative treatments to be used before a non-reversible destruction and function loss have occurred. The composition of the consortium include complementarities. Partners are involved to have large cohorts and biobank, to be excellent in understanding and modulating adaptive immunity, and to be able to take both these assets into clinical development of new therapeutics. The aim is to provide the basis for such development together with the EFPIA partners. All partners have a specific role in the development of specific technologies, mouse models, biobanks, systems for studying the adaptive immunity and drug development. Taken together the access for us and the EFPIA partners to this infrastructure and innovative projects will permit the development of new and innovative and ultimately curative therapies for early arthritis.

Keywords: biobanking,rheumatoid arthritis,animal models,inflammatory bowel disease
QUantitative Imaging in Cancer: CONnecting CEllular Processes with Therapy (QUIC-CONCEPT)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: Sweden,Belgium,United Kingdom,Germany,Netherlands,France,Netherlands,Netherlands,Belgium,Netherlands,France,Switzerland,Germany,France,United Kingdom
Call:  (IMI-JU-02-2009, 2009)
Start date: 2011-09-01
End date: 2018-06-30
Duration (months): 82.0
Total project cost (EUR): 15505915.0
EU funding (EUR): 7000000.0
Participants: 24
Project status: CLOSED

The QuIC-ConCePT consortium has 2 objectives: 1.(90% of resource, WP2-5) to qualify 3 specific imaging biomarkers (IBs) of tumour cell proliferation, apoptosis, and necrosis, to allow drug developers to demonstrate reliably modulation of these pathologic processes in tumours in patients in realistic trials. Our vision for January 2016 is that drug developers can incorporate these IBs for decision-making in Phase I trials of investigational therapies, confident that the IBs are technically valid, that a measured change in the IB faithfully reflects the desired change in the underlying tumour pathology, and that the IBs can be readily deployed in multiple cancer centres in a robust, consistent, ethical, and cost-effective way acceptable to patients. 2.(10% of resource, WP6) includes a portfolio of innovative approaches to devise, evaluate and introduce IBs of invasion and metastasis. The IBs of tumour cell proliferation and necrosis will be developed respectively from FLT PET and ADC MRI respectively. Initial apoptosis plans focus on ICMT11 PET, possibly with other IBs introduced later. The project will be delivered using a portfolio of animal (WP2), human (WP3), image analysis (WP4) and regulatory (WP5) work. The project will be coordinated and the interdependent workpackages integrated in WP1. These WPs will deliver image acquisition and analysis protocols which are technically valid, standardised and suitable for multicentre use. We will evaluate reproducibility, effects of intervention, timing, dose-response, and imaging-histopathology correlation in animals and patients. The project is timely, and highly likely to deliver IBs which will markedly improve drug development, and benefit cancer patients in Europe and globally. The managing entity (EORTC) is already world-leading in the qualification of IBs, and the consortium includes in the academic and EFPIA partners some of the world's most productive and innovative physicians and scientists in cancer imaging.

Keywords: oncology cancer imaging biomarker proliferation apoptosis necrosis invasion metastasis
Electronic Health Record systems for Clinical Research (EHR4CR)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: Sweden,France,Germany,Greece,Belgium,United Kingdom,United Kingdom,France,France,Germany,Germany,Switzerland,Poland,United Kingdom,United Kingdom,Germany,France,Germany,Belgium,Belgium,Germany,Belgium,United Kingdom,France,Germany,Belgium
Call:  (IMI-JU-02-2009, 2009)
Start date: 2011-03-01
End date: 2016-02-29
Duration (months): 60.0
Total project cost (EUR): 16643429.0
EU funding (EUR): 7194044.0
Participants: 35
Project status: CLOSED

Current medical needs, the growth of targeted therapies and personalized medicines, and escalating R&D costs result in formidable cost pressures on healthcare systems and the pharmaceutical industry. Clinical research is also growing in complexity, labour intensity and cost. There is a growing realization that the development and integration of Electronic Health Record systems (EHRs) for medical research can enable substantial efficiency gains, make Europe more attractive for R&D investment and provide patients better access to innovative medicines and improved health outcomes. EHRs can now be designed to seamlessly integrate with existing research platforms and healthcare networks to create opportunities for many stakeholders, including the pharmaceutical and bio-pharma industries. However, key challenges are compliance with various ethical, legal and privacy requirements (and acceptance by the general public, patients, and medical professionals), providing a platform that works across many EHR systems and is sustainable within a scalable business model. A 4-year project, EHR4CR will involve a team of recognised European academic and industrial partners. The project will build a platform to enable the use of EHR for more efficient medical research and run pilots (on interoperability, security, data quality, data storage solutions, organisational issues, accreditation and certification, etc) to demonstrate the viability and scalability of an EHR4CR business model. The EHR4CR project supports the IMI strategic agenda with an information gateway solution to enhance clinical research efficiency and innovation. A key IMI aspect is the development of a knowledge management capability that can, for example, provide information management support for other research on personalized medicines, now an IMI 2010 call topic. EHR4CR also supports other IMI R&D projects by enabling the use (and reuse) of large amounts of health data – in an ethical and cost-effective way.

Keywords: ehrs,clinical research,interoperability,business model
European Autism Interventions - A Multicentre Study for Developing New Medications (EU-AIMS)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: Switzerland,United Kingdom,Germany,Netherlands,United Kingdom,Iceland,Netherlands,France,Germany,Germany,Sweden,Belgium,France,Italy,United States,Germany,Netherlands,Denmark
Call:  (IMI-JU-03-2010, 2010)
Start date: 2012-04-01
End date: 2018-03-31
Duration (months): 72.0
Total project cost (EUR): 37480613.0
EU funding (EUR): 20490981.0
Participants: 28
Project status: CLOSED

Despite dramatic advances in molecular and imaging technologies, there are currently no effective pharmacological treatments for the core symptoms of autism spectrum disorder (ASD). Major obstructions to this include a lack of aetiologically-driven or pathophysiologically-accurate animal models; an absence of tests that indicate efficacy; and reliance of clinical trials on DSM/ICD10 categories which provide a collection of biologically heterogeneous patients. Further, even if novel treatments are developed there is no EU platform to clinically test them. Our hypothesis is that a focus on cross-species endophenotypes, finding biologically-homogenous groups of patients, and developing a clinical research network will overcome the limitations in target identification, early triage and clinical trials. Hence, leading European institutions and three SMEs will partner with the EFPIA to: a) develop in vitro models, and animal models that carry confirmed genetic risks, and in these animals to focus on cross-species endophenotypes (e.g., cognitive function, electrophysiology) to facilitate new drug discovery; b) validate the use of sMRI and fMRI-based endophenotypes in genetically-selected healthy volunteers, infants at risk for ASD, and children and adults (including twins) with and without ASD, as early and surrogate markers for efficacy; and to combine this with PET approaches to provide guidance regarding optimal clinical trial design; and c) identify biomarkers that can be used to stratify patients within an umbrella DSM-diagnosis, thus allowing for targeted clinical trials, individualized treatment and back-translation of subgroup-specific biomarkers into preclinical drug discovery. To increase the chance of a breakthrough we will implement new analytical approaches (e.g. support vector machine learning algorithms) and will actively collaborate with patient groups and other international efforts (e.g. the Autism Genetic Resource Exchange (AGRE)).

Keywords: autism,efpia,biomarkers,assays,drug discovery
Collaboration on the Optimisation of Macromolecular Pharmaceutical Access to Cellular Targets (COMPACT)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: Germany,Netherlands,Denmark,Germany,United Kingdom,Sweden,Norway,Austria,Germany,Switzerland,Belgium,Denmark,Finland,Netherlands,United Kingdom,United Kingdom,Germany,Denmark,Germany,Germany,Hungary
Call:  (IMI-JU-04-2011, 2011)
Start date: 2012-11-01
End date: 2017-10-31
Duration (months): 60.0
Total project cost (EUR): 29983730.0
EU funding (EUR): 10184909.0
Participants: 22
Project status: CLOSED

Most biopharmaceuticals (BP) currently on the market are recombinant proteins which are parenterally administered. These would benefit from more patient-friendly routes of administration. Moreover, new classes of BP (e.g. siRNA, miRNA, DARPins) with specificity for intracellular targets hold promise but await the advent of efficient delivery systems before their potential can be realised into therapeutic products. Solving the bottleneck of BP delivery is one of the main incentives of the pharmaceutical industry as this would allow a broadening of the spectrum of potential targets for therapeutic intervention needed to fill their drug pipelines. COMPACT represents Europe’s frontrunners in pharmaceutics, nanotechnology, biology, chemistry, engineering and imaging who will work in close collaboration with EFPIA on the delivery issues with BP. The main objectives are (1) to identify and understand transport pathways across biological barriers and cell membranes that can be utilized for delivery of BP, (2) to construct, characterise and preclincally validate BP formulations for non-invasive delivery of BP, with an emphasis on oral, airway and (trans)dermal delivery and for transport over the BBB. This will be achieved by setting up sophisticated in vitro models of biological barriers and appropriate animal models to find pathways that can be used for effective delivery of BP. In parallel, we will alter the BP either by chemical or biological engineering or by nano-formulations to enhance their uptake or transport over biological barriers.To be able to follow the transport,advanced imaging techniques will be utilised. The unique feature of this consortium is the alliance of experts in different research fields that complement each other in this challenging task. It is only the concerted action of such an interdisciplinary consortium that can make a difference in finding constructive solutions to the problem of poor bioavailability and target accessibility of BP.

Keywords: drug delivery,pharmaceutics,nanotechnology,biological engineering,chemical engineering,imaging,biopharmaceuticals